Table 3.
Multivariate Risk Factors for Herpes Zoster (HZ)
| HZ | No HZ | Hazard ratio (95% CI) | |
|---|---|---|---|
| N | 713 | 19,644 | |
| Age (Standard deviation) | 63.7 (11.5) | 62.9 (12.5) | 1.01 (1.01–1.02) |
| Male gender | 643 (90.2) | 17,843 (90.8) | 0.79 (0.61–1.02) |
| Prednisone use | 512 (71.8) | 12,895 (65.6) | 1.41 (1.19–1.67) |
| Medication group 1 | 208 | 9,463 | a |
| Medication group 2 | 409 | 12,479 | 1.34 (1.13–1.59) |
| Medication group 3 | 96 | 3,565 | 1.38 (1.08–1.77) |
| Hypertension | 528 (74.1) | 14,928 (76.0) | 1.06 (0.89–1.26) |
| Diabetes mellitus | 214 (30.0) | 6,131 (31.2) | 1.03 (0.87–1.21) |
| Malignancy | 173 (24.3) | 4,742 (24.1) | 1.24 (1.04–1.48) |
| Chronic lung disease | 306 (42.9) | 8,016 (40.2) | 1.28 (1.10–1.49) |
| Renal failure | 69 (9.7) | 1,792 (9.1) | 1.52 (1.18–1.97) |
| Liver disease | 46 (6.5) | 1,293 (6.6) | 1.36 (1.00–1.85) |
| Acquired Immune Deficiency Syndrome | 6 (0.8) | 83 (0.4) | 1.94 (0.87–4.36) |
| None of the above | 66 (9.3) | 1,820 (9.3) |
Note: Data are number (%) of patients, unless otherwise indicated. Statistically significant associations are in bold.
a
Reference group for medication groups 2 and 3